PE Tech Report


Like this article?

Sign up to our free newsletter

Beringea launches ProVen Legacy for mitigating IHT

Growth capital investor Beringea has launched a new lending company, ProVen Legacy, and closed its first two deals.

Healthcare media and marketing firm Cogora and fintech company Celoxica have received GBP500,000 and GBP250,000 loans respectively to support them in their next stage of growth.
Both companies are existing investments of Beringea’s VCT funds – ProVen VCT and ProVen Growth & Income VCT.
ProVen Legacy is designed to help investors mitigate inheritance tax (IHT) and preserve their capital. Investors should be able to benefit from up to 100 per cent tax relief from IHT on the value of their ProVen Legacy shares, provided that they have been held for at least two years and at the time of death.
This strategy is designed to meet the conditions of Business Property Relief, a tax incentive established by the government to encourage investment into trading businesses.
The investments into ProVen Legacy will be used to support growing companies across a range of industries as they enter the later stages of their scaling journeys, offering loans of up to GBP5 million.
Mark Taylor, partner at Beringea, says: “ProVen Legacy was created to help investors address a growing inheritance tax problem, while enabling Beringea to support later stage businesses as they enter a crucial stage of growth. These businesses, whether they are existing portfolio companies looking to raise additional capital through debt funding, or companies in which Beringea hasn’t previously invested, have the potential to scale significantly, making a considerable contribution to the UK economy as they do.
“Having already increased their global footprint in their respective fields, Cogora and Celoxica are the ideal businesses to receive the first loans from ProVen Legacy. We look forward to seeing them through this new and exciting phase, and to making more substantial loans to other companies as ProVen Legacy becomes more established.”
Cogora sits at the heart of a community of 220,000 healthcare professionals. As well as publishing industry magazine Pulse, Cogora provides market research and strategic consultancy to healthcare organisations and uses this insight to build marketing campaigns and education programmes. In 2015, Beringea supported Cogora’s acquisition of PCM Healthcare, adding specialist capabilities in continuing medical education (CME) and communications, as well as expanding operations from the EU to the global market. Cogora will use this new funding to focus on further growth in 2017.
Headquartered in the UK with offices across Europe and the US, Celoxica helps financial institutions, including tier one global banks and trading houses, optimise the performance of their trading platforms. The ultra-low latency processing technology gives clients accelerated access to market data for the main equity, options, futures, fixed income and FX markets in Europe and the US, supporting automated trading applications that immediately react to changing market conditions. It also enables brokers to offer ultra-low latency direct market access to their customers, including pre-trade checks. Having secured GBP1.5 million from Beringea in 2014, Celoxica will use this latest funding to further their sales growth in 2017.
Jean-Marc Bouhelier, executive chairman and CEO at Celoxica, says: “We’ve had a great relationship with Beringea since we first started working together in 2014. Beringea has been the perfect partner for us, through its network and its product offer, allowing us to scale-up our business without the need to raise further equity. ProVen Legacy is now an ideal vehicle for us – we were searching for a loan to support our sales growth in 2017. We’re grateful for the team’s support over the years and look forward to continuing our working relationship.”

Like this article? Sign up to our free newsletter